- Teleflex Incorporated TFX reported Q2 FY22 revenues of $704.5 million, down 1.3% Y/Y, up 2.3% on a constant currency basis, missing the consensus of $719.50 million.
- Lower sales from the Interventional Urology segment impacted the revenue. The company did not see the expected operating environment recovery in the Interventional Urology business during the second quarter.
- Adjusted diluted EPS increased 1.2% to $3.39, exceeding the consensus of $3.34.
- The gross margin remained flat at 59%.
- FY22 Guidance: Teleflex cut GAAP and constant currency revenue growth guidance to (0.45)% to 0.55% and 3.25% to 4.25%, respectively.
- The company lowered adjusted EPS to $13.00 - $13.40 from $13.70 - $14.30, below the consensus of $13.97.
- Price Action: TFX shares are down 6.53% at $249.13 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
